Table 4 Treatment-emergent AEs occurring... | American Society of Hematology

Table 4

Treatment-emergent AEs occurring in ≥25% of patients with B-cell lymphomas treated with single-agent brentuximab vedotin

AE	DLBCL (n = 49)						Other B-cell lymphomas (n = 19)
	Grade 1/2		Grade 3/4*		Total		Grade 1/2		Grade 3/4†		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Fatigue	21	43	6	12	27	55	5	26	0		5	26
Diarrhea	18	37	3	6	21	43	4	21	1	5	5	26
Neutropenia	2	4	18	37	20	41	1	5	5	26	6	32
Nausea	13	27	6	12	19	39	4	21	1	5	5	26
Decreased appetite	11	22	4	8	15	31	0		0		0
Pyrexia	13	27	1	2	15	31	5	26	0		5	26
Peripheral sensory neuropathy	12	24	2	4	14	29	4	21	0		4	21

AE	DLBCL (n = 49)						Other B-cell lymphomas (n = 19)
	Grade 1/2		Grade 3/4*		Total		Grade 1/2		Grade 3/4†		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Fatigue	21	43	6	12	27	55	5	26	0		5	26
Diarrhea	18	37	3	6	21	43	4	21	1	5	5	26
Neutropenia	2	4	18	37	20	41	1	5	5	26	6	32
Nausea	13	27	6	12	19	39	4	21	1	5	5	26
Decreased appetite	11	22	4	8	15	31	0		0		0
Pyrexia	13	27	1	2	15	31	5	26	0		5	26
Peripheral sensory neuropathy	12	24	2	4	14	29	4	21	0		4	21

All AEs were grade 3 with the exception of grade 4 neutropenia in 9 patients (18%).

All AEs were grade 3 with the exception of grade 4 neutropenia in 2 patients (11%).